touchPODCAST

touchPODCAST

By touchpodcastScience
Download on the App Store

touchPODCAST episodes

  • What’s new for eosinophilic esophagitis? A case-based discussion of patient care

    touchEXPERT OPINIONS for touchRESPIRATORY

    Listen to three experts in eosinophilic oesophagitis (EoE) to learn about the aetiology, pathophysiology and clinical manifestations of EoE, as well as the practical aspects of its diagnosis and management in children and adults based on clinical case studies.

    The experts

    • Dr Stuart Carr – Snö Asthma and Allergy, Abu Dhabi, UAE
  • Dr Mário Vieira – Hospital Pequeno Príncipe, Curitiba, PR, Brazil
  • Prof. Arjan Bredenoord – Amsterdam University Medical Center, Amsterdam, Netherlands

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: touchRESPIRATORY

    32 min
  • What’s new for eosinophilic esophagitis? A case-based discussion of patient care

    touchEXPERT OPINIONS for touchIMMUNOLOGY

    Listen to three experts in eosinophilic oesophagitis (EoE) to learn about the aetiology, pathophysiology and clinical manifestations of EoE, as well as the practical aspects of its diagnosis and management in children and adults based on clinical case studies.

    The experts

    • Dr Stuart Carr – Snö Asthma and Allergy, Abu Dhabi, UAE
  • Dr Mário Vieira – Hospital Pequeno Príncipe, Curitiba, PR, Brazil
  • Prof. Arjan Bredenoord – Amsterdam University Medical Center, Amsterdam, Netherlands

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: touchIMMUNOLOGY

    32 min
  • Higher-risk MDS and newly diagnosed AML What are the latest developments from EHA 2022

    touchCONGRESS for touchONCOLOGY

    Listen to Dr Esther Oliva (Italy) review key data presented at the EHA 2022 Hybrid Congress on recent developments in the treatment of higher-risk MDS and newly diagnosed AML; she offers her expert insights on their potential impact on future clinical practice, alongside those from Prof. Michael Heuser (Germany) and Dr Yishai Ofran (Israel). 

    OVERVIEW

    • Data review with Dr Oliva (0:00)
  • Expert interviews with Prof. Heuser, Dr Ofran and Dr Oliva, answering the questions below

    • INTERVIEW QUESTIONS

    1. Based on data presented at EHA 2022, which emerging treatments are most likely to impact future clinical practice for patients with HR-MDS? (30:08)
  • What do the latest data presented at EHA 2022 tell us about the clinical relevance of TP53 mutation in HR-MDS and newly diagnosed AML? (35:47)
  • To what extent will lower-intensity treatment regimens improve patient outcomes in newly diagnosed AML ineligible for intensive chemotherapy? Which of the emerging regimens do you think will be most important? (42:06)
  • Based on the latest research presented at EHA 2022, which prognostic tools and biomarkers do you consider most promising to support treatment decisions in HR-MDS or newly diagnosed AML? (49:55)

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.

    For further information visit our website: https://touchoncology.com/education/MDS-AML-EHA2022-touchcongress/

    57 min
  • Advances in the first-line treatment of ES-SCLC: From clinical data to daily practice

    touchPANEL DISCUSSION for touchONCOLOGY

    Listen to a panel of leading lung cancer experts share their perspectives on recent advances in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) and how they are changing clinical practice.

    The experts

    • Dr Marina Garassino - University of Chicago, Chicago, IL, USA
  • Dr Louis Paz-Ares - Hospital Universitario 12 de Octubre, Complutense University and Ciberonc, Madrid, Spain
  • DR Martin Edelman - Fox Chase Cancer Center, Philadelphia, PA, USA

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchoncology.com/ES-SCLC-first-line-treatment

    35 min
  • Investigating KRAS-G12C inhibitors: How might they improve outcomes for patients with solid tumours?

    touchTALKS for touchONCOLOGY

    Listen to an esteemed lung cancer expert discuss KRAS mutations in solid tumours, particularly non-small cell lung cancer and colorectal cancer, and consider the role of direct KRAS-G12C inhibitors in targeting these mutations and potential strategies to overcome resistance.

    The expert:

    • Prof. Tony Mok, Chinese University of Hong Kong, Hong Kong

    This touchPODCAST is for HCPs only. 

    This activity is funded by an unrestricted independent medical education grant from Novartis. This activity is provided by touchIME.

    For further information visit our website: https://touchoncology.com/education/kras-g12c-inhibitors-for-solid-tumours/

     

    31 min
  • Improving outcomes for patients with advanced renal cell carcinoma

    touchIN CONVERSATION for touchONCOLOGY


    Listen to Dr Cristina Suárez, a clinician in Spain with a specialist focus on genitourinary tumors, in conversation with Dr Toni Choueiri, a renal cell carcinoma (RCC) expert. They respond to questions submitted by the HCP audience and provide their expert insights on how emerging combination therapies in the first-line setting can improve outcomes for patients with advanced RCC.

    This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical education grant from Exelixis, Inc., and Merck and Co., Inc. This activity is jointly provided by USF Health and touchIME.


    For further information visit our website: https://touchoncologyime.org/in-conversation-improving-outcomes-advanced-rcc-role-of-emerging-combinations-first-line/

    37 min
  • Experts in paediatric endocrinology discuss the assessment and treatment of children with achondroplasia

    touchIN CONVERSATION for touchENDOCRINOLOGY

    Listen to Dr Nadia Merchant in conversation with Dr Andrew Dauber. They respond to questions submitted by the HCP audience and provide their expert insights on the physiology of normal and abnormal bone growth, and the assessment and treatment of children with achondroplasia.

    This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical education grant from BioMarin. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchendocrinologyime.org/in-conversation-paediatric-growth-patterns-and-their-impact-on-health-in-achondroplasia 

    36 min
  • Investigating KRAS-G12C inhibitors: How might they improve outcomes for patients with solid tumours?

    touchTALKS for touchRESPIRATORY

    Listen to an esteemed lung cancer expert discuss KRAS mutations in solid tumours, particularly non-small cell lung cancer and colorectal cancer, and consider the role of direct KRAS-G12C inhibitors in targeting these mutations and potential strategies to overcome resistance.

    The expert:

    • Prof. Tony Mok, Chinese University of Hong Kong, Hong Kong

    This touchPODCAST is for HCPs only. 

    This activity is funded by an unrestricted independent medical education grant from Novartis. This activity is provided by touchIME.

    For further information visit our website: https://www.touchrespiratory.com/education/kras-g12c-inhibitors-for-solid-tumours/

     

    31 min
  • Current and emerging treatments for chronic myeloid leukaemia: What have we learnt from the EHA Hybrid Conference 2022?

    touchCONGRESS for touchONCOLOGY

    Listen to Professor Giuseppe Saglio (Italy) cover key data presented at the EHA Hybrid Conference 2022 on the efficacy and safety of current and emerging treatments for CML, and how these may influence clinical practice, as well as expert insights and interpretation from Professor François-Xavier Mahon (France) and Professor Dietger Niederwieser (Germany).

    Overview

    • Data review with Professor Giuseppe Saglio (00:54)
  • Expert interview with Professor Giuseppe Saglio, Professor François-Xavier Mahon and Professor Dietger Niederwieser (32:50)

    • Interview questions

    • When considering the new 96-week data for asciminib from the ASCEMBL trial, how do you think these results will impact clinical practice? (35:00)
  • In patients with absence of an optimal response on therapy, what can we learn from new data on switching TKIs? (41:00)
  • What have we learnt about the clinical considerations for TKI discontinuation?(47:09)
  • Extended use of TKIs is now commonplace; what safety aspects have we seen from long-term follow-up studies?(52:26)
  • How should dose modifications be used for TKIs in clinical practice? (57:39)

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical educational grant from Novartis Pharmaceuticals. This activity is provided by touchIME.

    For further information visit our website: www.touchoncology.com

    1 hr 5 min
  • Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer

    touchIN CONVERSATION for touchONCOLOGY

    Listen to gynaecologic oncology specialists Prof. Nicoletta Colombo and Dr Natalia R Gómez-Hidalgo discuss three key topics relating to PARP inhibitors in the first-line maintenance setting for advanced ovarian cancer – rationale for use, which patients may particularly benefit, and key factors informing PARP inhibitor selection.

    Discussion on these themes is based on questions posed by healthcare professionals involved in the care of patients with ovarian cancer.

    This touchPODCAST is for HCPs only. 

    This activity is funded by an unrestricted independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.

    For further information visit our website: 

    https://touchoncology.com/education/parp-inhibitors-maintenance-inconvo2022/

    36 min

About touchPODCAST

From the publisher's feed

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites.